leadf
logo-loader
viewIXICO PLC

IXICO gets Huntington's disease contract over the line

The contract win was included in management's expectations of performance for the current financial year but adds to the company's strong order book

IXICO PLC -

IXICO PLC (LON:IXI) has secured a contract for neuroimaging solutions with a large global pharmaceutical company.

The Phase IIB trial will investigate an orphan drug designated clinical asset for the treatment of Huntington's disease (HD).

The AIM-listed artificial intelligence data analytics company said the contract win was included in management's expectations of performance for the current financial year but adds to the company's strong order book.

"We are delighted to be chosen to take part in this HD study to advance development of promising medical treatments for this devastating rare disease. This contract and new partnership will further endorse our breakthrough neuroimaging technologies with large pharma sponsors across the full spectrum of the drug development pathway,” said Lammert Albers, the chief commercial officer of IXICO in a statement.

Quick facts: IXICO PLC

Price: 90 GBX

AIM:IXI
Market: AIM
Market Cap: £42.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Brexit bells set to ring this Christmas Eve

The market report with Katie Pilbeam. FTSE 100 headed to the Christmas break in good cheer on the growing possibility that a Brexit deal will be announced today. The news overshadowed reports of another mutant coronavirus strain and helped London’s blue-chip index rise 19 to 6,515. Yes,...

on 24/12/20

2 min read